AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
When asked about On CNBC's "Mad Money Lightning Round," Jim Cramer said AbbVie Inc. (NYSE:ABBV) is doing "very, very well." However, he added that Abbott Laboratories (NYSE:ABT) remains his favorite in the group right now.
在CNBC的"瘋狂金錢閃電回合"中，吉姆·克萊默表示AbbVie公司（NYSE: ABBV）表現"非常非常好"。然而，他補充說Abbott Laboratories（紐約交易所：ABT）目前仍然是他在該集團中最喜歡的。
AbbVie was founded in 2013 when it became a separate company from Abbott.
AbbVie成立於2013年，成爲了與雅培公司分開的獨立公司。
On Oct. 9, UBS analyst Navin Jacob maintained AbbVie with a Neutral and raised the price target from $185 to $195.
在10月9日，瑞銀分析師納文·雅各布維持AbbVie公司的中立評級，並將價格目標從185美元上調至195美元。
When asked about Oracle (NYSE:ORCL), he said, "I like the prospects. But you're in it for the data center, and the data center business is excellent."
當被問及甲骨文公司（紐約交易所：ORCL）時，他說,"我喜歡其前景。但你選擇這家公司是爲了數據中心，而數據中心業務表現出色。"
Oracle recently launched Oracle Health Clinical Data Exchange, a cloud-based solution that streamlines medical claims processing through secure, automated data exchange between healthcare providers and payers.
甲骨文最近推出了Oracle Health Clinical Data Exchange，這是一種基於雲的解決方案，通過安全、自動化的數據交換簡化了醫療索賠處理，供應商與付款方之間的數據交換。
Core Scientific, Inc. (NASDAQ:CORZ) is a "mini-Palantir," Cramer said. He recommended buying Palantir (NYSE:PLTR).
Core Scientific，Inc.（納斯達克：CORZ）是一個"微型palantir"，克萊默表示。他建議購買palantir（紐交所：PLTR）。
On Oct. 11, B. Riley Securities analyst Lucas Pipes maintained Core Scientific with a Buy and raised the price target from $13 to $14.
10月110億。賴利證券分析師盧卡斯·派普斯維持對Core Scientific的買入評級，並將目標價格從13美元上調至14美元。
"I just don't want to go there. I know that it's a good company, but I just don't want to hurt anybody," Cramer said when asked about Clover Health Investments, Corp. (NASDAQ:CLOV).
"我只是不想這麼做。我知道這是一家很好的公司，但我只是不想傷害任何人，" 克萊默在被問到關於Clover Health Investments，Corp.（納斯達克：CLOV）時說。
The company recent said the Centers for Medicare and Medicaid Services (CMS) increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payments in 2026.
公司最近表示，康哲藥業提高了其PPO醫保計劃的星級評定至2025年的4星，影響到2026年的付款。
GXO Logistics (NYSE:GXO) is a "very valuable company," the "Mad Money" host said. "Just hold on."
GXO物流（紐交所：GXO）是一個"非常有價值的公司"，"瘋狂金錢"主持人表示。"只需持有。"
GXO recently announced a new transport partnership with Matalan.
GXO最近宣佈與Matalan達成了一項新的運輸合作。
Cramer said he really likes Sweetgreen, Inc. (NYSE:SG), adding that it is "terrific."
克萊默表示，他非常喜歡Sweetgreen公司（紐交所：SG），並補充說它"棒極了"。
Sweetgreen will release financial results for the third quarter after the closing bell on Thursday, Nov. 7.
Sweetgreen將於11月7日星期四收盤後發佈第三季度財務業績。
Price Action:
價格行動：
- Oracle shares gained 0.4% to settle at $174.77 on Wednesday.
- AbbVie shares fell 0.7% to close at $190.46.
- Core Scientific shares gained 2.2% to close at $13.25 on Wednesday.
- GXO Logistics shares gained 2.6% to settle at $62.95.
- Sweetgreen shares fell 0.7% to close at $37.94 on Wednesday.
- 甲骨文股價週三上漲0.4%，收於174.77美元。
- 艾伯維公司股價下跌0.7%，收於190.46美元。
- Core Scientific股票週三上漲2.2%，收於13.25美元。
- GXO物流股票週三上漲2.6%，收於62.95美元。
- Sweetgreen股票週三下跌0.7%，收於37.94美元。
- Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields
- 華爾街最準確的分析師對三隻消費股票的高股息收益率進行評估
Image: Shutterstock
圖片：shutterstock
